Iridin

Iridin is an isoflavone glycoside derived primarily from Iris species plants, where it is hydrolyzed in the body to its active aglycone form, irigenin. Its primary mechanisms include inhibition of pro-inflammatory cytokine production and induction of apoptosis in cancer cell lines via cell cycle arrest at the G2/M checkpoint.

Origin & History

Iridin is a natural isoflavone primarily isolated from the rhizome of Belamcanda chinensis (L.) DC., a plant used in traditional Chinese medicine. It is extracted using methods compatible with bioanalytical detection for pharmacological studies.

Historical & Cultural Context

Iridin is a key bioactive component in Belamcanda chinensis, traditionally used in Chinese medicine for its anti-inflammatory and antitumor activities. However, specific historical uses of iridin itself are not detailed in available sources.

Health Benefits

• Reduces inflammation and cytokine production in mouse models, indicating potential anti-inflammatory properties [1][2]. • Induces G2/M cell cycle arrest and apoptosis in AGS gastric cancer cells, suggesting antitumor effects [4]. • Inhibits abnormal glycolysis in immune cells, thereby suppressing inflammation [1][2]. • Promotes M2 macrophage polarization, supporting anti-inflammatory responses [1][2]. • Exhibits antiglycation effects, which may combat advanced glycation end-products [4][5].

How It Works

Iridin is metabolized to irigenin, which suppresses NF-κB signaling to reduce downstream production of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β. In gastric cancer cell lines, irigenin induces G2/M cell cycle arrest by downregulating cyclin B1 and CDC2 expression while activating caspase-3-dependent apoptotic pathways. Additionally, iridin inhibits abnormal glycolysis in activated immune cells by targeting key glycolytic enzymes, thereby modulating immune cell hyperactivation.

Scientific Research

There are no human clinical trials or meta-analyses available for iridin. All current evidence is based on preclinical studies conducted on cell lines and animal models, such as murine RAW264.7 macrophages and C57BL/6 mice [1][2][3][4][5].

Clinical Summary

Current evidence for iridin is limited almost entirely to in vitro cell culture studies and rodent models, with no published human clinical trials as of 2024. Mouse model studies have demonstrated measurable reductions in inflammatory cytokine levels and tumor growth inhibition, but these findings have not been validated in human subjects. In vitro studies using AGS gastric cancer cell lines showed dose-dependent induction of apoptosis, with specific concentrations in the micromolar range producing statistically significant effects. The overall evidence base must be characterized as preliminary, and extrapolation to human therapeutic use requires significant caution.

Nutritional Profile

Iridin is an isoflavone glycoside (iridoid-class flavonoid) derived primarily from Iris species (e.g., Iris versicolor, Iris germanica). It is not a macronutrient source but functions as a bioactive phytochemical. The core aglycone is irigenin, linked to a glucoside moiety. Typical concentrations in Iris rhizomes range from 0.1–0.5% dry weight. As a flavonoid glycoside, oral bioavailability is limited without gut microbial deglycosylation to release the active irigenin aglycone; absorption is estimated to be low-to-moderate (~10–30% relative bioavailability, comparable to other isoflavone glycosides). It contains no meaningful vitamins, minerals, fiber, or protein. Key bioactive mechanisms include NF-κB pathway inhibition, AMPK-mediated glycolysis suppression in macrophages, and caspase-3/9 activation in cancer cell lines. No established dietary reference values exist; research doses in mouse models typically range from 20–100 mg/kg body weight.

Preparation & Dosage

Preclinical studies used in vitro doses of 12.5-50 μM in RAW264.7 cells and oral doses of 20-80 mg/kg in mice. A rat pharmacokinetic study used a 100 mg/kg oral dose. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Iridin pairs well with Quercetin, as both inhibit NF-κB and pro-inflammatory cytokine production (TNF-α, IL-6) through complementary upstream targets — Iridin suppressing glycolytic reprogramming via AMPK while Quercetin inhibits IκB kinase, producing additive anti-inflammatory effects. Combining Iridin with Piperine (from black pepper) is strategically valuable because piperine inhibits P-glycoprotein efflux and glucuronidation enzymes (UGT1A1), potentially increasing the systemic bioavailability of irigenin aglycone by 20–50%, similar to piperine's documented enhancement of other flavonoid glycosides. Pairing with EGCG (Epigallocatechin gallate from green tea) may enhance the antitumor synergy, as both promote G2/M cell cycle arrest through overlapping but distinct mechanisms — Iridin activating checkpoint kinase pathways and EGCG downregulating cyclin B1/CDK1 expression — while EGCG's additional promotion of M2 macrophage polarization reinforces Iridin's documented immunomodulatory profile.

Safety & Interactions

Human safety data for iridin supplementation is largely absent, as no formal clinical toxicology trials have been conducted in human populations. As an isoflavone, iridin may exhibit weak estrogenic activity via binding to estrogen receptors, making it a theoretical concern for individuals with hormone-sensitive conditions such as estrogen receptor-positive breast cancer or endometriosis. Potential interactions with anticoagulant drugs like warfarin and immunosuppressant medications cannot be ruled out given its effects on immune cell signaling. Pregnant and breastfeeding women should avoid iridin supplementation due to the complete absence of safety data in these populations.